Public investors join Gilde for $280m Fund IV
Posted on 15 June, 2016 by Robert Lavine, news editor, Global Corporate Venturing
Investment firm Gilde Healthcare has closed its latest fund, which features the European Investment Fund, Danish Growth Fund and Dutch Venture Initiative II.
Netherlands-based healthcare investment firm Gilde Healthcare closed its latest fund at €250m ($280m) today after securing electronics and healthcare technology producer Royal Philips as cornerstone investor.
European Investment Fund (EIF), which participated through funding initiatives including European Recovery Program, state-owned Danish Growth Fund and Dutch Venture Initiative II – a vehicle backed by EIF, the Dutch Ministry of Economic Affairs and regional fund PPM Ost – also contributed to the fund, as did Johnson & Johnson Innovation – JJDC, the corporate venturing arm of healthcare group Johnson & Johnson and undisclosed fund-of-funds, endowments, family offices, entrepreneurs and Gilde Healthcare partners.
Gilde has now raised more than €800m for its healthcare funds. It operates separate funds that invest in healthcare technology developers and lower mid-market healthcare services providers.
Gilde Healthcare IV will make later-stage and growth equity investments in medical technology, digital health and therapeutics companies in Europe and North America, supplying between $17m and $28m to each portfolio company.
Pieter van der Meer, managing partner of Gilde Healthcare, said: “The healthcare landscape in the US and Europe is changing, driven by the need for more patient centric care and a much sharper focus on value.
“With our new fund we will continue to pursue our differentiated investment strategy of backing growth and later stage companies developing novel technologies or therapeutics that enable better healthcare outcomes at reduced costs.”
Philips was also cornerstone investor in Gilde’s Healthcare III fund, which closed at €145m in 2013. Gilde said it has exited 14 companies in the past three years, including nucleic acid drug developer Santaris, which was acquired by pharmaceutical company Roche for $450m in 2014.
– A version of this article first appeared on our sister site Global Corporate Venturing yesterday.
Copyright Mawsonia Limited 2010. Please don't cut articles from www.globalgovernmentventuring.com or the PDF and redistribute by email or post to the web without written permission.
Latest magazinePast Issues
Get full online access, the monthly magazine, weekly news alerts, special reports and more.See all subscription options